AbSci, a biotherapeutic discovery and manufacturing technologies company, has entered a collaboration with Sanofi. AbSci will apply its E.coli manufacturing platform, SoluPro, and its optimization assay system, to two of Sanofi’s biotherapeutic molecules. AbSci’s technology platform is designed with the ability to rapidly achieve optimized, scalable, high-quality, high-titer production of any class of biotherapeutic molecule, including traditionally difficult to manufacture molecules...